^
No biomarker
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: A1 - Approval
PD-L1 expression
Esophageal Squamous Cell Carcinoma
pembrolizumab
Sensitive: A1 - Approval
PD-L1 expression
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: B - Late Trials
EGFR overexpression
Esophageal Squamous Cell Carcinoma
erlotinib
Sensitive: B - Late Trials
No biomarker
Esophageal Squamous Cell Carcinoma
tislelizumab
Sensitive: B - Late Trials
PD-L1 expression
Esophageal Squamous Cell Carcinoma
nivolumab + ipilimumab
Sensitive: B - Late Trials
PD-L1 expression
Esophageal Squamous Cell Carcinoma
tislelizumab
Sensitive: B - Late Trials
PD-L1 expression
Esophageal Squamous Cell Carcinoma
sintilimab
Sensitive: B - Late Trials
PD-L1 overexpression
Esophageal Squamous Cell Carcinoma
pembrolizumab
Sensitive: B - Late Trials
NTRK3 fusion
Esophageal Squamous Cell Carcinoma
larotrectinib
Sensitive: C1 - Off-label
NTRK2 fusion
Esophageal Squamous Cell Carcinoma
larotrectinib
Sensitive: C1 - Off-label
NTRK1 fusion
Esophageal Squamous Cell Carcinoma
larotrectinib
Sensitive: C1 - Off-label
EGFR mutation
Esophageal Squamous Cell Carcinoma
afatinib
Sensitive: C1 - Off-label
HER-2 positive
Esophageal Squamous Cell Carcinoma
trastuzumab
Sensitive: C1 - Off-label
EGFR amplification
Esophageal Squamous Cell Carcinoma
afatinib
Sensitive: C2 – Inclusion Criteria
NRG1 overexpression
Esophageal Squamous Cell Carcinoma
AV-203
Sensitive: C3 – Early Trials
NDRG1 overexpression
Esophageal Squamous Cell Carcinoma
cisplatin + 5-fluorouracil
Resistant: C3 – Early Trials
SGK1 overexpression
Esophageal Squamous Cell Carcinoma
cisplatin + 5-fluorouracil
Resistant: C3 – Early Trials
AFAP1-AS1 overexpression
Esophageal Squamous Cell Carcinoma
FP
Resistant: C3 – Early Trials
PD-L1 expression
Esophageal Squamous Cell Carcinoma
camrelizumab
Sensitive: C3 – Early Trials
TLR signature
Esophageal Squamous Cell Carcinoma
tislelizumab
Sensitive: C3 – Early Trials
NDRG1-H
Esophageal Squamous Cell Carcinoma
cisplatin + 5-fluorouracil
Sensitive: C3 – Early Trials
DKK1 overexpression
Esophageal Squamous Cell Carcinoma
pembrolizumab + DKN-01
Sensitive: C3 – Early Trials
DKK1 overexpression
Esophageal Squamous Cell Carcinoma
DKN-01
Sensitive: C3 – Early Trials
NFKB1 expression
Esophageal Squamous Cell Carcinoma
rivoceranib
Sensitive: C3 – Early Trials
KDR expression
Esophageal Squamous Cell Carcinoma
rivoceranib
Sensitive: C3 – Early Trials
PD-L1 overexpression + CCL5 overexpression
Esophageal Squamous Cell Carcinoma
Immunotherapy
Sensitive: C3 – Early Trials
PD-L1 underexpression
Esophageal Squamous Cell Carcinoma
toripalimab + surufatinib
Sensitive: C3 – Early Trials
TTN D7145H
Esophageal Squamous Cell Carcinoma
cisplatin
Sensitive: C3 – Early Trials
MYH4 Q1210fs
Esophageal Squamous Cell Carcinoma
cisplatin
Sensitive: C3 – Early Trials
MRE11A underexpression
Esophageal Squamous Cell Carcinoma
cisplatin
Resistant: C3 – Early Trials
UBQLN4 overexpression
Esophageal Squamous Cell Carcinoma
cisplatin
Resistant: C3 – Early Trials
PD-L1 overexpression
Esophageal Squamous Cell Carcinoma
AB122
Sensitive: C3 – Early Trials
TP53 mutation
Esophageal Squamous Cell Carcinoma
SCT200
Sensitive: C3 – Early Trials
CD44 overexpression + CD24 underexpression
Esophageal Squamous Cell Carcinoma
cisplatin + 5-fluorouracil
Resistant: C3 – Early Trials
CD73 underexpression
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: C3 – Early Trials
CD73 underexpression
Esophageal Squamous Cell Carcinoma
pembrolizumab
Sensitive: C3 – Early Trials
PD-L1 overexpression
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: C3 – Early Trials
CD276 overexpression
Esophageal Squamous Cell Carcinoma
DS-7300
Sensitive: C3 – Early Trials
BRCA1 mutation
Esophageal Squamous Cell Carcinoma
FOLFOX
Sensitive: C4 – Case Studies
CDK14 overexpression
Esophageal Squamous Cell Carcinoma
cisplatin
Resistant: D – Preclinical
MACC1-AS1 overexpression
Esophageal Squamous Cell Carcinoma
cisplatin
Resistant: D – Preclinical
PARP1 expression
Esophageal Squamous Cell Carcinoma
anlotinib
Sensitive: D – Preclinical
TP53 mutation
Esophageal Squamous Cell Carcinoma
afatinib
Sensitive: D – Preclinical
CD31 expression
Esophageal Squamous Cell Carcinoma
anlotinib
Sensitive: D – Preclinical
BAX expression
Esophageal Squamous Cell Carcinoma
anlotinib
Sensitive: D – Preclinical
SOX9 overexpression
Esophageal Squamous Cell Carcinoma
nanoparticle albumin-bound rapamycin
Sensitive: D – Preclinical
EGFR overexpression
Esophageal Squamous Cell Carcinoma
nimotuzumab
Sensitive: D – Preclinical
LYPD3 expression
Esophageal Squamous Cell Carcinoma
BAY1129980
Sensitive: D – Preclinical
PER2 underexpression
Esophageal Squamous Cell Carcinoma
cisplatin
Sensitive: D – Preclinical